Business Segment Information - Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Business Segment Reconciliation Information
Net sales	$ 124,120	$ 95,690	$ 230,784	$ 181,312
Cost of sales	26,896	22,550	51,212	42,808
In-process research and development		2,500		14,229
Interest income	(2,574)	(2,828)	(5,650)	(5,911)
Interest expense	1,151	3,355	2,314	6,805
Charges associated with convertible senior notes		18,012		18,012
Income tax provision	248	331	574	708
Segment loss	(19,657)	(50,545)	(37,803)	(91,383)
Development and Commercialization of Ophthalmic Therapies
Business Segment Reconciliation Information
Net sales	124,120	95,690	230,784	181,312
Cost of sales	26,896	22,550	51,212	42,808
Sales, marketing and distribution	40,025	35,210	74,468	71,431
Research and development	25,802	19,805	48,724	38,238
Clinical	10,736	14,621	20,167	26,914
General and administrative	43,350	30,978	79,580	56,732
In-process research and development		2,500		14,229
Significant segment expenses	146,809	125,664	274,151	250,352
Interest income	(2,574)	(2,828)	(5,650)	(5,911)
Interest expense	1,151	3,355	2,314	6,805
Charges associated with convertible senior notes		18,012		18,012
Other (income) expense, net	(1,857)	1,701	(2,802)	2,729
Income tax provision	248	331	574	708
Segment loss	$ (19,657)	$ (50,545)	$ (37,803)	$ (91,383)